Top

Published in:

Open Access 01-01-2020 | Breast Cancer | Epidemiology

Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications

Published in: Breast Cancer Research and Treatment | Issue 1/2020

Abstract

Purpose

Female breast cancer demonstrates bimodal age frequency distribution patterns at diagnosis, interpretable as two main etiologic subtypes or groupings of tumors with shared risk factors. While RNA-based methods including PAM50 have identified well-established clinical subtypes, age distribution patterns at diagnosis as a proxy for etiologic subtype are not established for molecular and genomic tumor classifications.

Methods

We evaluated smoothed age frequency distributions at diagnosis for Carolina Breast Cancer Study cases within immunohistochemistry-based and RNA-based expression categories. Akaike information criterion (AIC) values compared the fit of single density versus two-component mixture models. Two-component mixture models estimated the proportion of early-onset and late-onset categories by immunohistochemistry-based ER (n = 2860), and by RNA-based ESR1 and PAM50 subtype (n = 1965). PAM50 findings were validated using pooled publicly available data (n = 8103).

Results

Breast cancers were best characterized by bimodal age distribution at diagnosis with incidence peaks near 45 and 65 years, regardless of molecular characteristics. However, proportional composition of early-onset and late-onset age distributions varied by molecular and genomic characteristics. Higher ER-protein and ESR1-RNA categories showed a greater proportion of late age-at-onset. Similarly, PAM50 subtypes showed a shifting age-at-onset distribution, with most pronounced early-onset and late-onset peaks found in Basal-like and Luminal A, respectively.

Conclusions

Bimodal age distribution at diagnosis was detected in the Carolina Breast Cancer Study, similar to national cancer registry data. Our data support two fundamental age-defined etiologic breast cancer subtypes that persist across molecular and genomic characteristics. Better criteria to distinguish etiologic subtypes could improve understanding of breast cancer etiology and contribute to prevention efforts.

Available only for authorised users

Butler EN, Tse CK, Bell ME, Conway K, Olshan AF, Troester MA (2016) Active smoking and risk of luminal and basal-like breast cancer subtypes in the Carolina breast cancer study. Cancer Causes Control 27(6):775–786. https://doi.org/10.1007/s10552-016-0754-1 CrossRefPubMedPubMedCentral

Allott EH, Cohen SM, Geradts J, Sun X, Khoury T, Bshara W, Zirpoli GR, Miller CR, Hwang H, Thorne LB, O’Connor S, Tse CK, Bell MB, Hu Z, Li Y, Kirk EL, Bethea TN, Perou CM, Palmer JR, Ambrosone CB, Olshan AF, Troester MA (2016) Performance of three-biomarker immunohistochemistry for intrinsic breast cancer subtyping in the AMBER consortium. Cancer Epidemiol Biomark Prev 25(3):470–478. https://doi.org/10.1158/1055-9965.EPI-15-0874 CrossRef

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874. https://doi.org/10.1073/pnas.191367098 CrossRefPubMedPubMedCentral

Anderson WF, Rosenberg PS, Prat A, Perou CM, Sherman ME (2014) How many etiological subtypes of breast cancer: two, three, four, or more? J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju165 CrossRefPubMedPubMedCentral

Anderson WF, Pfeiffer RM, Dores GM, Sherman ME (2006) Comparison of age distribution patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomark Prev 15(10):1899–1905. https://doi.org/10.1158/1055-9965.EPI-06-0191 CrossRef

Matsuno RK, Anderson WF, Yamamoto S, Tsukuma H, Pfeiffer RM, Kobayashi K, Devesa SS, Levine PH (2007) Early- and late-onset breast cancer types among women in the United States and Japan. Cancer Epidemiol Biomark Prev 16(7):1437–1442. https://doi.org/10.1158/1055-9965.EPI-07-0108 CrossRef

Dickens C, Pfeiffer RM, Anderson WF, Duarte R, Kellett P, Schuz J, Kielkowski D, McCormack VA (2016) Investigation of breast cancer sub-populations in black and white women in South Africa. Breast Cancer Res Treat 160(3):531–537. https://doi.org/10.1007/s10549-016-4019-1 CrossRefPubMed

Newman B, Moorman PG, Millikan R, Qaqish BF, Geradts J, Aldrich TE, Liu ET (1995) The Carolina breast cancer study: integrating population-based epidemiology and molecular biology. Breast Cancer Res Treat 35(1):51–60CrossRefPubMed

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410CrossRefPubMed

10.

Ma H, Lu Y, Marchbanks PA, Folger SG, Strom BL, McDonald JA, Simon MS, Weiss LK, Malone KE, Burkman RT, Sullivan-Halley J, Deapen DM, Press MF, Bernstein L (2013) Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women. Breast Cancer Res 15(5):R90. https://doi.org/10.1186/bcr3486 CrossRefPubMedPubMedCentral

11.

Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160–1167. https://doi.org/10.1200/JCO.2008.18.1370 CrossRefPubMedPubMedCentral

12.

Troester MA, Sun X, Allott EH, Geradts J, Cohen SM, Tse CK, Kirk EL, Thorne LB, Mathews M, Li Y, Hu Z, Robinson WR, Hoadley KA, Olopade OI, Reeder-Hayes KE, Earp HS, Olshan AF, Carey LA, Perou CM (2018) Racial differences in PAM50 subtypes in the Carolina breast cancer study. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djx135 CrossRefPubMed

13.

Williams LA, Butler EN, Sun X, Allott EH, Cohen SM, Fuller AM, Hoadley KA, Perou CM, Geradts J, Olshan AF, Troester MA (2018) TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases. NPJ Breast Cancer 4:13. https://doi.org/10.1038/s41523-018-0067-5 CrossRefPubMedPubMedCentral

14.

Elloumi F, Hu Z, Li Y, Parker JS, Gulley ML, Amos KD, Troester MA (2011) Systematic bias in genomic classification due to contaminating non-neoplastic tissue in breast tumor samples. BMC Med Genom 4:54. https://doi.org/10.1186/1755-8794-4-54 CrossRef

15.

Xia Y, Fan C, Hoadley KA, Parker JS, Perou CM (submitted) Genetic determinants of the molecular portraits of epithelial cancers. Nature

16.

Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Group M, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale AL, Brenton JD, Tavare S, Caldas C, Aparicio S (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403):346–352. https://doi.org/10.1038/nature10983 CrossRefPubMedPubMedCentral

17.

Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortes J, Parker JS, Perou CM, Baselga J (2014) Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju152 CrossRefPubMedPubMedCentral

18.

Brueffer C, Vallon-Christersson J, Grabau D, Ehinger A, Hakkinen J, Hegardt C, Malina J, Chen Y, Bendahl PO, Manjer J, Malmberg M, Larsson C, Loman N, Ryden L, Borg A, Saal LH (2018) Clinical value of RNA sequencing–based classifiers for prediction of the five conventional breast cancer biomarkers: a report from the population-based multicenter sweden cancerome analysis network—breast initiative. JCO Precis Oncol 2:1–18

19.

University of North Carolina Microarray Database. https://genome.unc.edu/pubsup/breastGEO/clinicalData.shtml

20.

Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, Anders C, Ewend M, Perou CM (2012) Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat 132(2):523–535. https://doi.org/10.1007/s10549-011-1619-7 CrossRefPubMed

21.

Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacon JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O’Shaughnessy J, Hortobagyi GN, Symmans WF (2011) A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305(18):1873–1881. https://doi.org/10.1001/jama.2011.593 CrossRefPubMedPubMedCentral

22.

Burnham KP, Anderson DR (2002) Model selection and multi-model inference: a practical information-theoretic approach, 2nd edn. Springer, New York

23.

Pfeiffer RM, Carroll RJ, Wheeler W, Whitby D, Mbulaiteye S (2008) Combining assays for estimating prevalence of human herpesvirus 8 infection using multivariate mixture models. Biostatistics 9(1):137–151. https://doi.org/10.1093/biostatistics/kxm018 CrossRefPubMed

24.

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. https://doi.org/10.1038/35021093 CrossRefPubMed

25.

Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, Chu A, Margolin AA, Van’t Veer LJ, Lopez-Bigas N, Laird PW, Raphael BJ, Ding L, Robertson AG, Byers LA, Mills GB, Weinstein JN, Van Waes C, Chen Z, Collisson EA, Cancer Genome Atlas Research N, Benz CC, Perou CM, Stuart JM (2014) Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158(4):929–944. https://doi.org/10.1016/j.cell.2014.06.049 CrossRefPubMedPubMedCentral

26.

Kerlikowske K, Gard CC, Tice JA, Ziv E, Cummings SR, Miglioretti DL, Breast Cancer Surveillance C (2017) Risk factors that increase risk of estrogen receptor-positive and -negative breast cancer. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djw276 CrossRefPubMed

27.

Palmer JR, Viscidi E, Troester MA, Hong CC, Schedin P, Bethea TN, Bandera EV, Borges V, McKinnon C, Haiman CA, Lunetta K, Kolonel LN, Rosenberg L, Olshan AF, Ambrosone CB (2014) Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium. J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju237 CrossRefPubMedPubMedCentral

28.

Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109(1):123–139. https://doi.org/10.1007/s10549-007-9632-6 CrossRefPubMed

29.

Sant M, Gatta G, Micheli A, Verdecchia A, Capocaccia R, Crosignani P, Berrino F (1991) Survival and age at diagnosis of breast cancer in a population-based cancer registry. Eur J Cancer 27(8):981–984CrossRefPubMed

30.

Muguti GI (1993) Experience with breast cancer in Zimbabwe. J R Coll Surg Edinb 38(2):75–78PubMed

31.

Chie WC, Chen CF, Lee WC, Chen CJ, Lin RS (1995) Age-period-cohort analysis of breast cancer mortality. Anticancer Res 15(2):511–515PubMed

32.

Anderson WF, Jatoi I, Devesa SS (2005) Distinct breast cancer incidence and prognostic patterns in the NCI’s SEER program: suggesting a possible link between etiology and outcome. Breast Cancer Res Treat 90(2):127–137. https://doi.org/10.1007/s10549-004-3777-3 CrossRefPubMed

33.

Jacquemier J, Padovani L, Rabayrol L, Lakhani SR, Penault-Llorca F, Denoux Y, Fiche M, Figueiro P, Maisongrosse V, Ledoussal V, Martinez Penuela J, Udvarhely N, El Makdissi G, Ginestier C, Geneix J, Charafe-Jauffret E, Xerri L, Eisinger F, Birnbaum D, Sobol H, European Working Group for Breast Screening P, Breast Cancer Linkage C (2005) Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 207(3):260–268. https://doi.org/10.1002/path.1845 CrossRefPubMed

34.

Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, Gautier C, Gauthier-Villars M, Bourstyn E, Clough KB, Magdelenat H, Pouillart P, Vincent-Salomon A, Fourquet A, Asselain B (2000) Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 18(24):4053–4059. https://doi.org/10.1200/JCO.2000.18.24.4053 CrossRefPubMed

35.

Collins LC, Botero ML, Schnitt SJ (2005) Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol 123(1):16–20CrossRefPubMed

36.

Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17(5):1474–1481CrossRefPubMed

37.

Rimm DL, Giltnane JM, Moeder C, Harigopal M, Chung GG, Camp RL, Burtness B (2007) Bimodal population or pathologist artifact? J Clin Oncol 25(17):2487–2488. https://doi.org/10.1200/JCO.2006.07.7537 CrossRefPubMed

38.

Butler EN, Bensen JT, Chen M, Conway K, Richardson DB, Sun X, Geradts J, Olshan AF, Troester MA (2018) Prediagnostic smoking is associated with binary and quantitative measures of ER protein and ESR1 mRNA expression in breast tumors. Cancer Epidemiol Biomark Prev 27(1):67–74. https://doi.org/10.1158/1055-9965.EPI-17-0404 CrossRef

39.

Muftah AA, Aleskandarany M, Sonbul SN, Nolan CC, Diez Rodriguez M, Caldas C, Ellis IO, Green AR, Rakha EA (2017) Further evidence to support bimodality of oestrogen receptor expression in breast cancer. Histopathology 70(3):456–465. https://doi.org/10.1111/his.13089 CrossRefPubMed

40.

Wang J, Wen S, Symmans WF, Pusztai L, Coombes KR (2009) The bimodality index: a criterion for discovering and ranking bimodal signatures from cancer gene expression profiling data. Cancer Inform 7:199–216PubMedPubMedCentral

Title: Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications
Publication date: 01-01-2020
Keywords: Breast Cancer
Breast Cancer
Published in: Breast Cancer Research and Treatment / Issue 1/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05442-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Distinct trajectories of fruits and vegetables, dietary fat, and alcohol intake following a breast cancer diagnosis: the Pathways Study

Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada

Optimized immunohistochemical detection of estrogen receptor beta using two validated monoclonal antibodies confirms its expression in normal and malignant breast tissues

Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies

COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells

Patient-reported outcomes and objective assessments with arm measurement and bioimpedance analysis for lymphedema among breast cancer survivors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer